Results 61 to 70 of about 1,652 (181)

Exploring Artificial Intelligence's Potential to Enhance Conventional Anticancer Drug Development

Drug Development Research, Volume 86, Issue 7, November 2025.
ABSTRACT Cancer affects one in three to four people globally, with over 20 million new cases and 10 million deaths annually, projected to rise to 35 million cases by 2050. Developing effective cancer treatments is crucial, but the drug discovery process is a highly complex and expensive endeavor, with success rates sitting well below 10% for oncologic ...
Sorin‐Ștefan Bobolea, Miruna‐Ioana Hinoveanu, Andreea Dimitriu, Miruna‐Andrada Brașoveanu, Cristian‐Nicolae Iliescu, Cristina‐Elena Dinu‐Pîrvu, Mihaela Violeta Ghica, Valentina Anuța, Lăcrămioara Popa, Răzvan Mihai Prisada   +9 more
wiley   +1 more source

Figure S3 from Wee1 Kinase Inhibitor AZD1775 Effectively Sensitizes Esophageal Cancer to Radiotherapy

, 2023
<p>Kaplan-Meier survival curves demonstrating percent of mice free from tumor doubling are shown for both FLO1 and OE33 xenograft models.</p>
Terence M. Williams, Steven H. Lin, Junran Zhang, Eric D. Miller, Andrew J. Hu, Tianyun Li, Cory J. Pettit, Changxian Shen, Linlin Yang   +8 more
openaire   +1 more source

Transforming Cancer Diagnostics: The Emergence of Liquid Biopsy and Epigenetic Markers

MedComm, Volume 6, Issue 9, September 2025.
Liquid biopsy is becoming prominent in cancer diagnostics and management due to its advantage of being noninvasive compared to traditional tissue biopsy. This technique processes blood sample to identify circulating biomarkers like cell‐free DNA, circulating tumor cell, and exosomal RNA.
Debalina Saha, Pritam Kanjilal, Mandeep Kaur, Soumya V. Menon, Ayash Ashraf, M. Ravi Kumar, Taha Alqahtani, Shikha Atteri, Daniel Ejim Uti, Bikram Dhara   +9 more
wiley   +1 more source

Synthetic Lethality‐Based Targets and Their Exploration in Tumour Combination Strategies

Journal of Cellular and Molecular Medicine, Volume 29, Issue 16, August 2025.
ABSTRACT Synthetic lethality (SL) not only addresses the challenge of drug resistance associated with classical targeted therapies but also offers innovative therapeutic approaches for previously ‘undruggable’ targets, such as deletion mutations in tumour suppressor genes.
Lingya Wu, Yixuan Deng, Zhe Lei, Yuhong Wang, Shan Huang   +4 more
wiley   +1 more source

Loss of SETD2 in wild‐type VHL clear cell renal cell carcinoma sensitizes cells to STF‐62247 and leads to DNA damage, cell cycle arrest, and cell death characteristic of pyroptosis

Molecular Oncology, Volume 19, Issue 4, Page 1244-1264, April 2025.
Vulnerability to the small molecule STF‐62247 is observed in SETD2‐inactivated VHL‐positive clear cell renal cell carcinoma (ccRCC) cells. DNA damage and loss of CDC25A leads to cell cycle arrest in S phase. Cleavage of caspase‐3 (CASP3) and gasdermin E (GSDME) suggests cell death by pyroptosis.
Mathieu Johnson, Sandra Turcotte
wiley   +1 more source

Supplementary data from The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Cancer

, 2018
Supplementary Figure 1. Combination treatment with olaparib/AZD1775 is effective in select SCLC CDX models. Mice bearing CDX3 (a), CDX4 (b), CDX8 (c), or CDX8p (d) tumors were treated with vehicles (black) AZD1775 (red), olaparib (green), or the ...
Francesca Trapani (12566881), Alice Lallo (15010112), Maximillian W. Schenk (15010121), Kristopher K. Frese (14919695), Lynsey Priest (2173084), Crispin Miller (848347), Zhongwu Lai (1896406), Adina Hughes (6158855), Christopher J. Morrow (6278141), Cassandra L. Hodgkinson (14988795), Robert Sloane (15010115), Nicole Simms (15010124), Kathryn L. Simpson (1284804), Mark J. O'Connor (14875842), Fiona Blackhall (594412), Stewart Brown (7399892), Elaine Cadogan (1822777), Sakshi Gulati (15010118), Garima Khandelwal (243038), Caroline Dive (421487), Melanie Galvin (12068545)   +20 more
core   +1 more source

Supplemental Figure 2 from WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non–Small Cell Lung Cancer

, 2017
Active AMPK protein expression in H2030 isogenic cell lines treated with AZD1775 or 2DG.
Kelley O'Brien (14926139), Timothy G. Whitsett (12196547), Landon J. Inge (14926145), Vashti M. Carson (14926142), Amanda L. Richer (14926136), Jacqueline M. Cala (5634860)   +5 more
core   +1 more source

Development and Characterization of a Wee1 Kinase Degrader [PDF]

, 2020
The G1/S cell cycle checkpoint is frequently dysregulated in cancer, leaving cancer cells reliant on a functional G2/M checkpoint to prevent excessive DNA damage.
Fischer, Eric S, Gray, Nathanael S, Scott, David A, Doctor, Zainab M, Nowak, Radosław P, Eleuteri, Nicholas A, Sorger, Peter K, Li, Zhengnian, Olson, Calla M, Pinch, Benika J, Donovan, Katherine A, Chung, Mirra, Mills, Caitlin E   +12 more
core   +1 more source

Figure S4 from Wee1 Kinase Inhibitor AZD1775 Effectively Sensitizes Esophageal Cancer to Radiotherapy

, 2023
<p>Weight changes in nude mice compared to baseline (pre-therapy) weights over time (days). Note that radiation treatment was associated with decline in weight which recovered with time. Treatments occurred during Days 1-5 as described in the text.</p>
Terence M. Williams, Steven H. Lin, Junran Zhang, Eric D. Miller, Andrew J. Hu, Tianyun Li, Cory J. Pettit, Changxian Shen, Linlin Yang   +8 more
openaire   +1 more source

A WEE1 Inhibitor Analog of AZD1775 Maintains Synergy with Cisplatin and Demonstrates Reduced Single-Agent Cytotoxicity in Medulloblastoma Cells

, 2016
The current treatment for medulloblastoma includes surgical resection, radiation, and cytotoxic chemotherapy. Although this approach has improved survival rates, the high doses of chemotherapy required for clinical efficacy often result in lasting ...
Michael F. Wempe (339637), Vladimir Amani (1443661), Donald S. Backos (1443664), Sujatha Venkataraman (194808), Nicholas K. Foreman (1443667), Christopher J. Matheson (1443670), Philip Reigan (159804), Peter S. Harris (351495), Andrew M. Donson (1443673), Rajeev Vibhakar (247074)   +9 more
core   +1 more source